Strategies to improve the use of evidence-based heart failure therapies

Reviews in Cardiovascular Medicine

Volumn 6, Issue SUPPL. 2, 2005, Pages

  Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blockers; Angiotensin converting enzyme inhibitors; Cardiac resynchronization therapy; Evidence based therapy; Heart failure; Implantable cardioverter defibrillator

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COST OF ILLNESS; DEFIBRILLATOR; DOSE RESPONSE; DRUG INDICATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SURVEY; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MORBIDITY; MORTALITY; OUTPATIENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; TREATMENT INDICATION; TREATMENT OUTCOME; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; HEART PACING; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC PACING, ARTIFICIAL; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 18944371072     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001; 38:2101-2113.
2. Heart Failure Society of America. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail. 1999;5:357-382.
3. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J. 1999; 20:1182-1190.
4. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61.
5. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-1307.
6. Havranek EP, Wolfe P, Masoudi FA, et al. Provider and hospital characteristics associated with geographic variation in the evaluation and management of elderly patients with heart failure. Arch Intern Med. 2004;164:1186-1191.
7. Fonarow GC, Yancy CW, Chang SF. Variation in heart failure quality of care indicators among U.S. hospitals: analysis of 230 hospitals in ADHERE [abstract]. Circulation. 2003;108(suppl IV):IV-447.
8. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
9. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501-508.
10. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
11. McAlister FA, Ezekowitz JA, Wiebe N, et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med. 2004;141:381-390.
12. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289:2685-2694.
13. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
14. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456.
15. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
16. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348: 1309-1321.
17. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
18. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002;360:1631-1639.
19. Ansari M, Shilpak MG, Heindenreich PA, et al. Improving guideline adherence: a randomized trial evaluating strategies to increase β-blocker use in heart failure. Circulation. 2003;107: 2799-2804.
20. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345:1667-1675.
21. Joint Commission on Accreditation of Healthcare Organizations. Overview of the Heart Failure (HF) Core Measure Set by joint Commission on Accreditation of Healthcare Organizations. Available at: http://www.jcaho.org/pms/core+measures/hf_overview.htm.
22. Ashton CM, Kuykendall DH, Johnson ML, et al. The association between the quality of inpatient care and early readmission. Ann Intern Med. 1995;122:415-421.
23. Pfeffer MA, Stevenson LW, Beta-adrenergic blockers and survival in heart failure. N Engl J Med. 1996;334:1396-1397.
24. Fonarow GC. The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. Rev Cardiovasc Med. 2002;3(suppl 3):S2-S10.
25. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 1997;30:725-732.
26. Rich MW. Heart failure disease management: a critical review. J Card Fail. 1999;5:64-75.
27. Gattis W, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534-1541.
28. Pearson RR, Horne BD, Maycock CA, et al. An institutional heart failure medication program reduces future cardiovascular readmissions and mortality: an analysis of 19,083 heart failure patients. Circulation. 2001;104(suppl II):II-838.
29. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289:712-718.
30. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87: 819-822.
31. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J.. 2004;148:43-51.
32. LaBresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164:203-209.
33. Hanumanthu S, Butler J, Chomsky D, et al. Effect of a heart failure program on hospitalization frequency and exercise tolerance. Circulation. 1997;96:2842-2848.
34. West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol. 1997;79:58-63.
35. Rich MW, Becham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333: 1190-1195.
36. Stewart S, Horowitz JD. Home-based intervention in congestive heart failure. Circulation. 2002;105:2861-2866.
37. Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol. 2002; 39:83-89.
38. Kimmelstiel C, Levine D, Perry K, et al. Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial. Circulation. 2004; 110:1450-1455.
39. McAlister FA, Lawson FME, Teo KK, et al. A systemic review of randomized trials of disease management programs in heart failure. Am J Med. 2001;110:378-384.
40. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004;44:810-819.
41. Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 2004;291:1358-1367.